Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA

Maria Månsson Martinez, Falastin Salami, Helena Elding Larsson, Jorma Toppari, Åke Lernmark, Jukka Kero, Riitta Veijola, Jaakko J Koskenniemi, Päivi Tossavainen, Markus Lundgren, Henrik Borg, Anastasia Katsarou, Marlena Maziarz, Carina Törn, TEDDY Family (TEFA) Study Group, Maria Månsson Martinez, Falastin Salami, Helena Elding Larsson, Jorma Toppari, Åke Lernmark, Jukka Kero, Riitta Veijola, Jaakko J Koskenniemi, Päivi Tossavainen, Markus Lundgren, Henrik Borg, Anastasia Katsarou, Marlena Maziarz, Carina Törn, TEDDY Family (TEFA) Study Group

Abstract

Aim: The aim of the present study was to assess beta cell function based on an oral glucose tolerance test (OGTT) in participants with single islet autoantibody or an intravenous glucose tolerance test (IvGTT) in participants with multiple islet autoantibodies.

Materials and methods: Healthy participants in Sweden and Finland, between 2 and 49.99 years of age previously identified as positive for a single (n = 30) autoantibody to either insulin, glutamic acid decarboxylase, islet antigen-2, zinc transporter 8 or islet cell antibodies or multiple autoantibodies (n = 46), were included. Participants positive for a single autoantibody underwent a 6-point OGTT while participants positive for multiple autoantibodies underwent an IvGTT. Glucose, insulin and C-peptide were measured from OGTT and IvGTT samples.

Results: All participants positive for a single autoantibody had a normal glucose tolerance test with 120 minutes glucose below 7.70 mmol/L and HbA1c values within the normal range (<42 mmol/mol). Insulin responses to the glucose challenge on OGTT ranged between 13.0 and 143 mIU/L after 120 minutes with C-peptide values between 0.74 and 4.60 nmol/L. In Swedish participants, the first-phase insulin response (FPIR) on IvGTT was lower in those positive for three or more autoantibodies (n = 13; median 83.0 mIU/L; range 20.0-343) compared to those with two autoantibodies (n = 15; median 146 mIU/L; range 19.0-545; P = .0330).

Conclusion: Participants positive for a single autoantibody appeared to have a normal beta cell function. Participants positive for three or more autoantibodies had a lower FPIR as compared to participants with two autoantibodies, supporting the view that their beta cell function had deteriorated.

Trial registration: ClinicalTrials.gov NCT02605148.

Keywords: HbA1c; intravenous glucose tolerance test; oral glucose tolerance test.

Conflict of interest statement

The authors declare that there is no conflict of interests associated with this study.

© 2020 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.

References

    1. Siljander HT, Hermann R, Hekkala A, et al. Insulin secretion and sensitivity in the prediction of type 1 diabetes in children with advanced beta‐cell autoimmunity. Eur J Endocrinol. 2013;169(4):479‐485.
    1. Elding Larsson H, Larsson C, Lernmark A, DiAPREV‐IT study group . Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention. Acta Diabetol. 2015;52(3):473‐481.
    1. Helminen O, Aspholm S, Pokka T, et al. OGTT and random plasma glucose in the prediction of type 1 diabetes and time to diagnosis. Diabetologia. 2015;58(8):1787‐1796.
    1. Helminen O, Aspholm S, Pokka T, et al. HbA1c Predicts Time to Diagnosis of Type 1 Diabetes in Children at Risk. Diabetes. 2015;64(5):1719‐1727.
    1. Bingley PJ, Boulware DC, Krischer JP. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia. 2016;59(3):542‐549.
    1. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473‐2479.
    1. Delli AJ, Vaziri‐Sani F, Lindblad B, et al. Zinc transporter 8 autoantibodies and their association with SLC30A8 and HLA‐DQ genes differ between immigrant and Swedish patients with newly diagnosed type 1 diabetes in the Better Diabetes Diagnosis study. Diabetes. 2012;61(10):2556‐2564.
    1. Redondo MJ, Sosenko J, Libman I, et al. Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated with Older Age and Insulin Resistance. J Clin Endocrinol Metab. 2019;105(5):1629‐1640.
    1. Andersson C, Kolmodin M, Ivarsson SA, et al. Islet cell antibodies (ICA) identify autoimmunity in children with new onset diabetes mellitius negative for other islet cell antibodies. Pediatr Diabetes. 2014;15(5):336‐44.
    1. Vehik K, Cuthbertson D, Boulware D, et al. Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth. Diabetes Care. 2012;35(9):1821‐1825.
    1. Jacobsen LM, Larsson HE, Tamura RN, et al. Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children. Pediatr Diabetes. 2019;20(3):263‐270.
    1. Huus K, Akerman L, Raustorp A, Ludvigsson J. Physical Activity, Blood Glucose and C‐Peptide in Healthy School‐Children, a Longitudinal Study. PLoS One. 2016;11(6):e0156401.
    1. Sabek OM, Redondo MJ, Nguyen DT, et al. Serum C‐peptide and osteocalcin levels in children with recently diagnosed diabetes. Endocrinol Diabetes Metab. 2019;3(1):e00104.
    1. Törn C, Landin‐Olsson M, Lernmark Å, et al. Prognostic factors for the course of B‐cell function in autoimmune diabetes. J Clin Endocrinol Metab. 2000;85:4619‐4623.
    1. Ling Q, Lu J, Li J, Xu Q, Zhu D, Bi Y. Risk of beta‐cell autoimmunity presence for progression to type 1 diabetes: A systematic review and meta‐analysis. J Autoimmun. 2018;86:9‐18.
    1. Jacobsen LM, Bocchino L, Evans‐Molina C, et al. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia. 2019;63(3):588‐596.
    1. Koskinen MK, Helminen O, Matomaki J, et al. Reduced beta‐cell function in early preclinical type 1 diabetes. Eur J Endocrinol. 2016;174(3):251‐259.
    1. Koskinen MK, Lempainen J, Loyttyniemi E, et al. Class II HLA Genotype Association With First‐Phase Insulin Response Is Explained by Islet Autoantibodies. J Clin Endocrinol Metab. 2018;103(8):2870‐2878.
    1. Koskinen MK, Mikk ML, Laine AP, et al. Longitudinal Pattern of First‐Phase Insulin Response Is Associated With Genetic Variants Outside the Class II HLA Region in Children With Multiple Autoantibodies. Diabetes. 2020;69(1):12‐19.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj